<DOC>
	<DOCNO>NCT01626820</DOCNO>
	<brief_summary>This study design test immunogenicity term Hemagglutination Inhibition ( HI ) antibodies three vaccine influenza strain reactogenicity safety Fluviral® contain influenza strain recommend 2012-2013 season .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Fluviral® ( 2012/2013 Season ) Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female 18 year age old time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . Administration influenza vaccine within 6 month precede study start plan use vaccine study period . Administration vaccine ( ) within 30 day prior study enrolment study period . Clinically virologically confirm influenza infection within six month precede study vaccination . Acute disease and/or fever time enrolment . Significant acute chronic , uncontrolled medical psychiatric neurological illness . Any confirm suspected immunosuppressive immunodeficient condition . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Insulindependent diabetes mellitus . Presence blood dyscrasia , include hemoglobinopathy myelo lymphoproliferative disorder . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccine dose . A history demyelinate disease include Multiple Sclerosis GuillainBarré syndrome . History chronic alcohol abuse and/or drug abuse deem investigator render potential subject unable/unlikely provide accurate safety report . Any significant disorder coagulation increase risk intramuscular injection treatment coumadin derivative heparin . Persons receive prophylactic antiplatelet medication , e.g . lowdose aspirin , without clinicallyapparent bleeding tendency eligible . Administration immunoglobulins and/or blood product within three month precede administration study vaccine plan study . Any known suspected allergy constituent Fluviral® and/or history anaphylactic type reaction consumption egg , and/or reaction product contain mercury . A history severe adverse reaction previous influenza vaccination . Pregnant and/or lactating/nursing female . Any condition , opinion investigator , prevents subject participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza</keyword>
	<keyword>Safety</keyword>
	<keyword>Adults</keyword>
	<keyword>Fluviral</keyword>
</DOC>